Topoisomerase I protein expression in primary colorectal cancer and recurrences after 5-FU-based adjuvant chemotherapy
- 29 June 2007
- journal article
- Published by Springer Science and Business Media LLC in Zeitschrift für Krebsforschung und Klinische Onkologie
- Vol. 133 (12), 1011-1015
- https://doi.org/10.1007/s00432-007-0253-6
Abstract
Our aim was to investigate whether chemotherapy with 5-FU induces an alteration in the levels of topoisomerase I (topo I) in colorectal neoplastic tissues Twenty-five colorectal cancer patients were included in our study; these had undergone surgical resection of the primary tumor, received post-operatively 5-FU-based adjuvant chemotherapy and then suffered from recurrences. In a standard three-step immunohistochemical procedure, a monoclonal antibody to topo I was applied in both specimens from each patient (one from the primary location and a second one from the recurrence). Statistical analysis was subsequently performed. Malignant cells from the recurrences displayed a statistical significant increase, concerning the levels of topoisomerase I, by comparison with the primary tumors (P = 0.01). The increase in topo I levels did not demonstrate significant correlations with Duke’s stage (Fisher’s Exact Test P value = 0.496), differentiation grade (P value = 0.661), localization (P value = 0.072), patient sex (P value = 0.434), nor with relapse free interval (P value = 0.493). There was a statistically significant relationship between the age of patients and increase in topo I levels (P = 0.011). Topo I expression may be part of the malignant cells’ phenotype in recurrent colorectal carcinomas, suggesting a potential role for Topo I in the acquisition of a metastatic phenotype. The increase of topo I immunohistochemical status is likely to be attributed to 5-FU and given the fact that high levels of topo I correlate with sensitivity to camptothecin, advanced colorectal cancer patients seem to benefit from topo I targeted anticancer drug therapy.This publication has 36 references indexed in Scilit:
- Topoisomerase‐I, thymidylate synthase primary tumour expression and clinical efficacy of 5‐FU/CPT‐11 chemotherapy in advanced colorectal cancer patientsInternational Journal of Cancer, 2004
- DNA Topoisomerases: Structure, Function, and MechanismAnnual Review of Biochemistry, 2001
- Predictive value of topoisomerase IIalpha immunostaining in urothelial bladder carcinomaJournal of Clinical Pathology, 2001
- Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal CancerThe New England Journal of Medicine, 2000
- A Model for the Mechanism of Human Topoisomerase IScience, 1998
- Immunohistochemical detection of DNA topoisomerase I in formalin fixed, paraffin wax embedded normal tissues and in ovarian carcinomas.Molecular Pathology, 1997
- CPT-11 in human colon-cancer cell lines and xenografts: Characterization of cellular sensitivity determinantsInternational Journal of Cancer, 1997
- Eukaryotic DNA topoisomerases IBiochimica et Biophysica Acta (BBA) - Gene Structure and Expression, 1995
- DNA topoisomerase I is involved in both repression and activation of transcriptionNature, 1993
- Fluorinated Pyrimidines, A New Class of Tumour-Inhibitory CompoundsNature, 1957